CN101698050A - Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation - Google Patents
Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation Download PDFInfo
- Publication number
- CN101698050A CN101698050A CN200810113154A CN200810113154A CN101698050A CN 101698050 A CN101698050 A CN 101698050A CN 200810113154 A CN200810113154 A CN 200810113154A CN 200810113154 A CN200810113154 A CN 200810113154A CN 101698050 A CN101698050 A CN 101698050A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- atrial fibrillation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides an application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation. Clinic trials prove that the traditional Chinese medicine composite has the functions of tonifying qi and yin, promoting blood circulation, removing meridian obstruction, clearing away the heart fire and tranquillizing, can be used for treating paroxysmal atrial fibrillation, can obviously improve clinic symptoms and performs favourable treating effect.
Description
Technical field
The present invention relates to the application of a kind of Chinese medicine composition in preparation treatment paroxysmal auricular fibrillation medicine.Belong to the Chinese herbal and crude drugs preparations technical field.
Background technology
Atrial fibrillation (abbreviation atrial fibrillation) is adult's common arrhythmia, and ventricular beat is fast and irregular during the atrial fibrillation outbreak, between 120-180 time/minute.The atrial fibrillation overwhelming majority occurs among the patient of organic heart disease, and is wherein common with rheumatic disease of mitral valve change, coronary heart disease and hypertensive cardiopathy.The heart disease of also visible and primary cardiac myopathy, hyperthyroidism, chronic constrictive pericarditis and other causes of disease.Behind hypothermic anesthesia, thoracic cavity and the operation on heart, actute infection and cerebrovascular accident also can cause, minority can occur in digitalism and metastatic tumo(u)r is invaded and during heart.Long-time paroxysm of part or persistency patients with atrial fibrillation there is no the evidence of organic heart disease.Be called the special property sent out atrial fibrillation again.
The pathogeny of atrial fibrillation generally has two kinds of theories.One is unusual self-disciplining; Two are the miniature theory of turning back of circulatory motion or many places.Present most scholar thinks, the above-mentioned two kinds of genesis mechanism that may all can not satisfactorily explain atrial fibrillation separately.Most probable reason is, the impulsion that one or several ectopic pacemaker produces in the atrium, in the atrium, spread take place in the process that many places are miniature and turn back due to.Also have and think have the big reentrant cycle of multi-source to split into subring at any position in atrium, irregular biography is due to the ventricle.
The symptom had palpitation of atrial fibrillation clinical manifestation, uncomfortable in chest and alarmed.Ventricular Rate can make obviously reduction of stroke volume, coronary circulation and brain blood for reducing near normal and do not have the fast and cardiac function of patient, the especially Ventricular Rate of organic heart disease when relatively poor, causes acute heart failure, shock, faintness or angina pectoris attacks.Atrial fibrillation also easily causes thrombosis in the room after taking place, and the part thrombosis breaks away from can cause body circulation arterial thrombosis, the most common with cerebral embolism clinically, often causes dead or invalid.
Atrial fibrillation is divided into two types of paroxysmal and persistency, more, can change the persistency atrial fibrillation into through outbreak repeatedly when sending out during the paroxysmal atrial fibrillation.How paroxysmal auricular fibrillation is caused by organic heart disease.Its main complication is a cerebral embolism, and the patient is disabled even death.The paroxysmal atrial fibrillation is a kind of form of expression of organic heart disease, also may be the independent disease due to the degeneration of sinuatrial node own.[Chen Haozhu the 10th edition P1149 in practical internal medicine People's Health Publisher October in 1997].
According to traditional Chinese medical science network ens morbi, ARR generation is many, and heart network void is not flourish to be hindered with the channels stasis of blood because of deficiency of both QI and YIN causes.Network void is the Rong Ze lack of preservation of spirit not; The channels stasis of blood hinders with the passing of time blood stasis dispelling, all can cause malaise, ARR situation occurs.[Wu inquires into sick new ideas of mountain range channels cardiovascular system and treatment. difficult disease magazine, 2005,4 (5): 285-287]
The present invention is the improvement invention of carrying out on the basis of ZL02146572.X patent application, quotes in full the content of this patent document record at this.
Summary of the invention
The purpose of this invention is to provide the application of this Chinese medicine composition in preparation treatment paroxysmal atrial fibrillation medicine.It is characterized in that this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
The weight ratio of crude drug is preferably in the Chinese medicine composition of the present invention:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
The weight ratio of crude drug also is preferably in the Chinese medicine composition of the present invention:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
In the application of the present invention, the active component of this Chinese medicine composition is made by the following step:
A) people participates in 70% alcohol reflux three times, and merge extractive liquid, filters, and concentrates oven dry, the fine powder that is ground into;
B) Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times jointly, and merge extractive liquid, filters spissated extractum;
C) fine powder that is broken into of Eupolyph aga sinesis Walker;
D) Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, merge extractive liquid,, spissated extractum.
E) with step b) and d) merging of gained extractum, the fine drug powder of adding step c) gained, oven dry is ground into fine powder, adds step a) gained fine drug powder, and mixing promptly gets this Chinese medicine composition active component.
In the application of the present invention, described Chinese medicine composition is a capsule, tablet, electuary, a kind of in powder or the oral liquid formulations, for above-mentioned dosage form can be realized, need when these dosage forms of preparation, to add the pharmacy acceptable auxiliary, for example: filler, disintegrating agent, lubricant, suspending agent, binding agent, sweeting agent, correctives, antiseptic etc., filler comprises: starch, pregelatinized Starch, lactose, mannitol, chitin, microcrystalline Cellulose, sucrose etc., disintegrating agent comprises: starch, pregelatinized Starch, microcrystalline Cellulose, carboxymethyl starch sodium, crospolyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, cross-linking sodium carboxymethyl cellulose etc., lubricant comprises: magnesium stearate, sodium lauryl sulphate, Pulvis Talci, silicon dioxide etc., suspending agent comprises: polyvinylpyrrolidone, microcrystalline Cellulose, sucrose, agar, hydroxypropyl emthylcellulose etc., binding agent comprises, starch slurry, polyvinylpyrrolidone, hydroxypropyl emthylcellulose etc., sweeting agent comprises: saccharin sodium, Aspartane, sucrose, cyclamate, enoxolone etc., correctives comprises: sweeting agent and various essence, and antiseptic comprises: parabens, benzoic acid, sodium benzoate, sorbic acid and its esters, benzalkonium bromide, the acetic acid chloroethene is fixed, the Folium eucalypti globueli (Eucalyptus globulus Labill.) wet goods.
Above-described medicine capsule, its preparation method are to be made by following steps:
A, take by weighing Chinese crude drug, clean according to the crude drug part by weight;
B, people participate in 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and concentrates, and 80 order fine powders are pulverized in oven dry, and are standby;
C, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times, and 3 hours for the first time, each 2 hours merge extractive liquid, filtered later on, reclaim ethanol, and extractum is standby;
D, Eupolyph aga sinesis Walker are broken into 80 order fine powders, and be standby;
E, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis add 9 times of water gagings and decoct 2 times, and 3 hours for the first time, 2 hours merge extractive liquid, filter, are condensed into extractum for the second time, and were standby;
F, step c and e gained extractum are merged, add the fine powder of step b, steps d gained, oven dry is ground into 80 order fine powders, and mixing incapsulates, promptly.
The consumption of Chinese medicine composition of the present invention by active component crude drug gross weight, is 7-28 gram/day, but takes every day once, preferably divides and takes for 2-4 time.
The paroxysmal atrial fibrillation is common clinically arrhythmia, the paroxysmal atrial fibrillation is treated correction and reduced outbreak, can improve patient's symptom, prevent from and delay paroxysmal atrial fibrillation progress to be permanent atrial fibrillation, active treatment causes the underlying diseases of paroxysmal atrial fibrillation, improve blood supply of cardiac muscle, reduce atrial pressure, alleviate ventricular hypertrophy, all help the control of paroxysmal atrial fibrillation and change sinus rate into, because common antiarrhythmic drug is not satisfied to the curative effect of paroxysmal atrial fibrillation, so the effective Chinese prescription treatment of screening paroxysmal atrial fibrillation is the direction of the combination of Chinese and Western medicine.
According to traditional Chinese medical science network ens morbi, ARR generation is many, and heart network void is not flourish to be hindered with the channels stasis of blood because of deficiency of both QI and YIN causes.Network void is the Rong Ze lack of preservation of spirit not; The channels stasis of blood hinders with the passing of time blood stasis dispelling, all can cause malaise, ARR situation occurs.
Symptoms such as medicine composite for curing paroxysmal atrial fibrillation of the present invention can obviously improve cardiopalmus, uncomfortable in chest, sweating, breathes hard, weak, dizziness. reduce atrial fibrillation frequency and single duration of seizure. and then improve the life quality of patients with atrial fibrillation.
The compound preparation that preparation of the present invention is made up of Radix Ginseng, Radix Ophiopogonis, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos, Fructus Corni, Herba Taxilli etc. has the Comprehensive Treatment effect of supplementing QI and nourishing YIN, promoting blood circulation to remove obstruction in the collateral, clearing away heart-fire for tranquillization.The invention provides the new application of a kind of Chinese medicine composition in the medicine of preparation treatment paroxysmal atrial fibrillation, prove by clinical trial, this pharmaceutical composition is applied to paroxysmal atrial fibrillation patient, has obtained the remarkable result of total effective rate 81.82%, can be used for the treatment of paroxysmal atrial fibrillation.
Essence for a better understanding of the present invention in " treatment paroxysmal atrial fibrillation " result of the test, illustrates its new purposes at pharmaceutical field below by this pharmaceutical composition of clinical observation.
Experimental example: (it is attached to mountain range hospital that this test data derives from Hebei Medical University)
One, data and method:
1.1 physical data 80 examples all still have the patient of the paroxysmal atrial fibrillation outbreak that takes place frequently, male 48 examples, women 32 examples, average 58.4 ± 8 years old of age, paroxysmal atrial fibrillation medical history 6-24 month more than at least 3 months through the routine treatment.Underlying diseases is coronary heart disease 60 examples, rheumatic heart disease 11 examples, acute viral myocarditis 1 example, the special property sent out atrial fibrillation 8 examples.The average outbreak persistent period is 30 minutes to 6 days.Clinical symptoms shows as: palpitation and restlessness, the deficiency of vital energy are weak, suffocating pain over the chest, insomnia and dreamful sleep, spiritlessness and sparing of words, sweating while acting, the dark violet thick fur of body of the tongue, thready and weak pulse or knot or short, and Chinese medical discrimination is deficiency of both QI and YIN, the resistance of the heart network stasis of blood.
Be divided into 2 groups at random, every group of each 40 example.
Inclusion criteria: be diagnosed as atrial fibrillation through medical history, health check-up and electrocardiogram, Ventricular Rate 〉=100 time/minute.
Exclusion standard: hyperthyroidism, sick sinus syndrome.
Basis medicining condition: all use common drugs such as resisting hypertension, coronary dilating, anticoagulant, blood sugar lowering, used isoptin, propafenone, metoprolol treatment at the paroxysmal atrial fibrillation.
1.2 the Therapeutic Method matched group is only taken basic medication, the capsule (by the preparation of embodiment 1 method) that the oral the present invention in basic medication of treatment group is made, each 4, every day 3 times; 4 all 1 courses of treatment, 3 courses of treatment of logotype, the responder continues to take, and outpatient service in every month is followed up a case by regular visits to 1-2 time, recording ecg 1 time, record paroxysmal atrial fibrillation attack times, clinical symptoms is improved situation, and adverse effect is when having the outbreak of paroxysmal atrial fibrillation, instrucion patient institute at any time makes electrocardiographic recorder, have a blood test after 3 courses of treatment sugar, blood fat, hepatic and renal function, blood viscosity.
1.3 criterion of therapeutical effect symptom score: symptom, tongue arteries and veins, atrial fibrillation attack times before and after the record patient treatment, respectively to cardiopalmus, uncomfortable in chest, perspire, breathe hard, symptom such as weak, dizziness carries out the sxemiquantitative scoring.Wherein cardiopalmus is as cardinal symptom, respectively with 2,4,6 respectively expression light, in, severe; All the other symptoms are light with 1,2,3 expressions, in, severe.The dissociate mensuration of divergence (Pd), QT interval (QTc), ST section (STc), T ripple (Tc) of ECG P ripple: under quiescent condition, do standard 12 lead electrocardiogram (chart speed 25mm/s, gain 1mv/10mm) before and after the treatment.
The calculating of Pd: the P wave number is measured from P ripple starting point and equipotential line intersection point, to P ripple emphasis and equipotential line intersection point.After measuring 8 above P wave in lead values, when the P ripple is maximum phase (Pmax) and P ripple hour mutually (Pmin) difference be Pd.
The calculating of QTc, Tc, STc: measure the QT interval from each QRS ripple initial part to T ripple terminal point, measure the ST section simultaneously, the T ripple time limit serve as accurate mensuration T ripple Origin And Destination with the intersection point of T ripple upstroke, decent and baseline.
If any the U ripple, then be as the criterion with the incisura between T ripple and the U ripple, determine T ripple terminal point.Every example is measured and is led more than 8,3 QT of continuous measurement interval on each leads, ST section, T involve the R-R interval before it, calculate the meansigma methods (correction) of three QTc, Tc, STc then, get all QTc of each experimenter, Tc, STc meansigma methods at last as statistical value according to Bazett ' s formula.
1.4 statistical method: continuous data represents that with x ± s different time points relatively adopts the t check, is the difference significance with P＜0.05.
Two, result
Treatment group treatment back symptom score: Pd, QTc and the equal significance of treatment money comparing difference (P＜0.01 or P＜0.05), difference nonsignificance (P＞0.05) before and after STc, the Tc treatment.See Table 1.
Symptom score Pd, QTc, Tc, STc (x ± s) relatively before and after the table 1 data set treatment
Annotate: with compare * P＜0.05, #P＜0.01 before the treatment
Two groups of curative effect comparative results see Table 2, and treatment group total effective rate is significantly higher than matched group (P＜0.05).
Table 2 liang group curative effect comparative result
Annotate: compare * P＜0.05 with matched group
The result shows medicine composite for curing paroxysmal atrial fibrillation patient of the present invention, can obviously improve clinical symptoms, and untoward reaction is few, and its mechanism is worth further research to be explored, so that promote the use of.
Medicine of the present invention is to be prepared from by following examples, and following specific embodiment is an explanation of the invention.
The specific embodiment
Following embodiment is used to illustrate the preparation of Chinese medicine composition of the present invention, but it can not constitute any restriction to scope of the present invention.
Embodiment 1
For the ease of the application of this Chinese medicine composition, this Chinese medicine composition is prepared as capsule
Prescription:
Radix Ginseng 89g 112g Radix Ophiopogonis Fructus Corni 224g Radix Salviae Miltiorrhizae 224g
Semen Ziziphi Spinosae (parched) 186g Herba Taxilli 186g Radix Paeoniae Rubra 89g Eupolyphaga Seu Steleophaga 75g
Radix Et Rhizoma Nardostachyos 89g Rhizoma Coptidis 45g Fructus Schisandrae Sphenantherae 67g Os Draconis 149g
Preparation method:
A, take by weighing Chinese crude drug, clean according to recipe quantity;
B, people participate in 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and concentrates, and 80 order fine powders are pulverized in oven dry, and are standby;
C, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times, and 3 hours for the first time, each 2 hours merge extractive liquid, filtered later on, reclaim ethanol, and extractum is standby;
D, Eupolyph aga sinesis Walker are broken into 80 order fine powders, and be standby;
E, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis add 9 times of water gagings and decoct 2 times, and 3 hours for the first time, 2 hours merge extractive liquid, filter, are condensed into extractum for the second time, and were standby;
F, step c and e gained extractum are merged, add the fine powder of step b, steps d gained, oven dry is ground into 80 order fine powders, mixing, 1000 capsules of packing into.
Usage and consumption: oral.One time 2～4,3 times on the one.
Embodiment 2
For the ease of the application of this Chinese medicine composition, this Chinese medicine composition is prepared as tablet
Prescription:
Radix Ginseng 45g 112g Radix Ophiopogonis Fructus Corni 224g Radix Salviae Miltiorrhizae 225g
Semen Ziziphi Spinosae (parched) 186g Herba Taxilli 186g Radix Paeoniae Rubra 89g Radix Et Rhizoma Nardostachyos 45g
Eupolyphaga Seu Steleophaga 35g Rhizoma Coptidis 45g Fructus Schisandrae Sphenantherae 67g Os Draconis 149g
Preparation method:
A, take by weighing Chinese crude drug, clean according to recipe quantity;
B, people participate in 50% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and concentrates, and 80 order fine powders are pulverized in oven dry, and are standby;
C, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 50% alcohol reflux 3 times, and each 2 hours, merge extractive liquid, filtered, and reclaims ethanol, and extractum is standby;
D, Eupolyph aga sinesis Walker are broken into 80 order fine powders, and be standby;
E, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis add 9 times of water gagings and decoct 2 times, and each 2 hours merge extractive liquid, filter, are condensed into extractum, and are standby;
F, step c and e gained extractum are merged, add the fine powder of step b, steps d gained, oven dry is made 1000 tablets of tablets according to the conventional formulation method.
Embodiment 3
For the ease of the application of this Chinese medicine composition, this Chinese medicine composition is prepared as granule
Prescription:
Radix Ginseng 90g 135g Radix Ophiopogonis Fructus Corni 270g Radix Salviae Miltiorrhizae 200g
Semen Ziziphi Spinosae (parched) 150g Herba Taxilli 150g Radix Paeoniae Rubra 100g Eupolyphaga Seu Steleophaga 100g
Radix Et Rhizoma Nardostachyos 95g Rhizoma Coptidis 60g Fructus Schisandrae Sphenantherae 75g Os Draconis 150g
Preparation method:
A, take by weighing Chinese crude drug, clean according to recipe quantity;
B, people participate in 90% alcohol reflux twice, and each 2 hours, merge extractive liquid, filtered, and concentrates, and 80 order fine powders are pulverized in oven dry, and are standby;
C, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 80% alcohol reflux 2 times, and each 2 hours, merge extractive liquid, filtered, and reclaims ethanol, and extractum is standby;
D, Eupolyph aga sinesis Walker are broken into 80 order fine powders, and be standby;
E, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis add 9 times of water gagings and decoct 2 times, and each 3 hours merge extractive liquid, filter, are condensed into extractum, and are standby;
F, step c and e gained extractum are merged, add the fine powder of step b, steps d gained, oven dry makes 1000 gram granules according to the conventional formulation method, and packing promptly.
Claims (9)
1. the application of Chinese medicine composition in preparation treatment paroxysmal auricular fibrillation medicine is characterized in that this Chinese medicine composition is made by following bulk drugs:
Radix Ginseng 45-180 part, Radix Ophiopogonis 50-200 part, Fructus Corni 125-450 part, Radix Salviae Miltiorrhizae 125-450 part, Semen Ziziphi Spinosae (parched) 95-400 part, Herba Taxilli 95-400 part, Radix Paeoniae Rubra 45-200 part, Eupolyphaga Seu Steleophaga 35-150 part, Radix Et Rhizoma Nardostachyos 45-200 part, Rhizoma Coptidis 25-90 part, Fructus Schisandrae Sphenantherae 35-150 part, Os Draconis 75-300 part.
2. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
89 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 224 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 75 parts of Eupolyphaga Seu Steleophagas, 89 parts of Radix Et Rhizoma Nardostachyos, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
3. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
45 parts of Radix Ginsengs, 112 parts of Radix Ophiopogonis, 224 parts of Fructus Corni, 225 parts of Radix Salviae Miltiorrhizaes, 186 parts of Semen Ziziphi Spinosae (parched)s, 186 parts of Herba Taxillis, 89 parts of Radix Paeoniae Rubra, 45 parts of Radix Et Rhizoma Nardostachyos, 35 parts of Eupolyphaga Seu Steleophagas, 45 parts of Rhizoma Coptidis, 67 parts of Fructus Schisandrae Sphenantheraes, 149 parts of Os Draconis.
4. application as claimed in claim 1 is characterized in that, this Chinese medicine composition is made by following bulk drugs:
90 parts of Radix Ginsengs, 135 parts of Radix Ophiopogonis, 270 parts of Fructus Corni, 200 parts of Radix Salviae Miltiorrhizaes, 150 parts of Semen Ziziphi Spinosae (parched)s, 150 parts of Herba Taxillis, 100 parts of Radix Paeoniae Rubra, 100 parts of Eupolyphaga Seu Steleophagas, 95 parts of Radix Et Rhizoma Nardostachyos, 60 parts of Rhizoma Coptidis, 75 parts of Fructus Schisandrae Sphenantheraes, 150 parts of Os Draconis.
5. as the described application of claim 1-4, it is characterized in that the active component of this Chinese medicine composition is made by the following step:
A, people participate in 70% alcohol reflux three times, and merge extractive liquid, filters, and concentrates, and oven dry is ground into fine powder;
B, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 70% alcohol reflux 3 times, and merge extractive liquid, filters, and is condensed into extractum;
C, Eupolyph aga sinesis Walker are broken into fine powder;
D, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis decoct with water 2 times, and merge extractive liquid, is condensed into extractum;
E, step b and d gained extractum are merged, add the fine drug powder of step c gained, oven dry is ground into fine powder, adds step a gained fine drug powder, and mixing promptly gets this Chinese medicine composition active component.
6. as each described application among the claim 1-4, it is characterized in that described Chinese medicine composition is capsule, tablet, electuary, powder or oral liquid.
7. according to the preparation method of the described medicine capsule of claim 6, it is characterized in that it being to make by following steps:
A, take by weighing Chinese crude drug, clean according to the crude drug part by weight;
B, people participate in 70% alcohol reflux three times, and 3 hours for the first time, each 2 hours later on, merge extractive liquid, filtered, and concentrates, and 80 order fine powders are pulverized in oven dry, and are standby;
C, Fructus Schisandrae Sphenantherae, Fructus Corni, Radix Salviae Miltiorrhizae, Rhizoma Coptidis, Radix Et Rhizoma Nardostachyos add 8 times of amount 70% alcohol reflux 3 times, and 3 hours for the first time, each 2 hours merge extractive liquid, filtered later on, reclaim ethanol, and extractum is standby;
D, Eupolyph aga sinesis Walker are broken into 80 order fine powders, and be standby;
E, Radix Ophiopogonis, Semen Ziziphi Spinosae (parched), Herba Taxilli, Radix Paeoniae Rubra, Os Draconis add 9 times of water gagings and decoct 2 times, and 3 hours for the first time, 2 hours merge extractive liquid, filter, are condensed into extractum for the second time, and were standby;
F, step c and e gained extractum are merged, add the fine powder of step b, steps d gained, oven dry is ground into 80 order fine powders, and mixing incapsulates, promptly.
8. as the described application of claim 1-4, it is characterized in that described paroxysmal auricular fibrillation is spy's property sent out atrial fibrillation of no organic heart disease.
9. as the described application of claim 1-4, it is characterized in that described paroxysmal auricular fibrillation underlying diseases is an organic heart disease.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101131546A CN101698050B (en) | 2008-05-28 | 2008-05-28 | Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008101131546A CN101698050B (en) | 2008-05-28 | 2008-05-28 | Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101698050A true CN101698050A (en) | 2010-04-28 |
| CN101698050B CN101698050B (en) | 2012-06-27 |
Family
ID=42146515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008101131546A Active CN101698050B (en) | 2008-05-28 | 2008-05-28 | Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101698050B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451366A (en) * | 2010-10-25 | 2012-05-16 | 韩丽华 | Anti-arrhythmia traditional Chinese medicine capsule |
| CN104721547A (en) * | 2015-03-14 | 2015-06-24 | 包汉雨 | Chinese medicinal composition for cardioversion of patients with atrial fibrillation |
| CN105194313A (en) * | 2015-10-27 | 2015-12-30 | 菏泽海诺知识产权服务有限公司 | Traditional Chinese medicine treating paroxysmal atrial fibrillation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1188159C (en) * | 2002-10-24 | 2005-02-09 | 河北以岭医药研究院有限公司 | Medicines composition for treating coronary heart disease ventricular premature beat and its prepn |
-
2008
- 2008-05-28 CN CN2008101131546A patent/CN101698050B/en active Active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102451366A (en) * | 2010-10-25 | 2012-05-16 | 韩丽华 | Anti-arrhythmia traditional Chinese medicine capsule |
| CN104721547A (en) * | 2015-03-14 | 2015-06-24 | 包汉雨 | Chinese medicinal composition for cardioversion of patients with atrial fibrillation |
| CN105194313A (en) * | 2015-10-27 | 2015-12-30 | 菏泽海诺知识产权服务有限公司 | Traditional Chinese medicine treating paroxysmal atrial fibrillation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101698050B (en) | 2012-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101632796B (en) | Application of Chinese medicinal composition in preparing medicament for treating acute heart failure | |
| CN102908513B (en) | Application of traditional Chinese medicine composition in medicine for treating arrhythmia | |
| CN101698050B (en) | Application of traditional Chinese medicine composite in preparing medicine treating paroxysmal atrial fibrillation | |
| CN107158347A (en) | A kind of pharmaceutical composition and preparation method and purposes for treating heart disease | |
| CN101167838B (en) | Traditional Chinese medicinal preparation for treating coronary heart disease and angina pectoris and its preparing process | |
| CN101632783B (en) | Application of Chinese medicinal composition in preparing medicament for treating cor pulmonale | |
| CN101411764A (en) | Use of Chinese medicinal composition in preparing medicament for treating degenerative cardiac valve disease of old age | |
| CN101632784B (en) | Application of Chinese medicinal composition in preparing medicament for treating acute myocardial infarction | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN101653550A (en) | Chinese medicinal composition in preparation of medicament for treating type II diabetes | |
| CN102210807B (en) | Application of traditional Chinese medicine composition in preparation of medicaments for treating angina pectoris | |
| CN106620253B (en) | Traditional Chinese medicine composition for treating bradyarrhythmia | |
| CN103623207A (en) | Applications of traditional Chinese medicine composition in preparation of medicines used for treating chronic heart failure together with arrhythmia | |
| CN101313990B (en) | Application of a Chinese medicinal composition in preparing medicament for treating neurosis | |
| CN101590178B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating refractory premature beat of elderly patient | |
| CN102309675B (en) | Application of Chinese medicine composition in preparing medicines for treating sick sinus syndrome | |
| CN102210806A (en) | Application of Chinese medicinal composition to preparation of medicaments for treating nonorganic heart disease arrhythmia | |
| CN101698052B (en) | Application of traditional Chinese medicine composite in preparing medicine treating acute myocardial infarction associated with arrhythmia | |
| CN101411814B (en) | Use of Chinese medicinal composition in preparing medicament for treating intraventricular block | |
| CN103933340B (en) | A kind of application of Chinese medicine composition in the drug of preparation treatment pneumoconiosis | |
| CN101559162B (en) | Application of traditional Chinese medicine composition in preparing medicament for curing slow arrhythmia | |
| CN101744905B (en) | Applications of Chinese medicinal composition in preparation of medicament for treating pulmonary heart disease | |
| CN102309674B (en) | Use of traditional Chinese drug composition in preparing drug for treating atrioventricular block | |
| CN107184938A (en) | The pharmaceutical composition and preparation method and purposes of a kind of propafenone on ventricular premature beats | |
| CN101411813B (en) | Use of Chinese medicinal composition in preparing medicament for treating chronic systolic heart failure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |